Mark S. Ordan Sells 27,600 Shares of Pediatrix Medical Group, Inc. (NYSE:MD) Stock

Pediatrix Medical Group, Inc. (NYSE:MD) Director Mark S. Ordan sold 27,600 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the completion of the transaction, the director now directly owns 138,683 shares in the company, valued at approximately $2,128,784.05. This represents a 16.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Pediatrix Medical Group Stock Down 4.1 %

Shares of NYSE MD opened at $14.15 on Friday. The stock has a market capitalization of $1.22 billion, a P/E ratio of -4.62, a PEG ratio of 2.18 and a beta of 1.55. The stock’s fifty day moving average is $12.53 and its 200 day moving average is $9.84. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $16.41. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same period last year, the firm earned $0.29 EPS. The business’s quarterly revenue was up .9% compared to the same quarter last year. Sell-side analysts forecast that Pediatrix Medical Group, Inc. will post 1.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC boosted its stake in shares of Pediatrix Medical Group by 25.6% in the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after purchasing an additional 622 shares in the last quarter. nVerses Capital LLC bought a new position in Pediatrix Medical Group in the 2nd quarter valued at approximately $31,000. Innealta Capital LLC acquired a new stake in Pediatrix Medical Group in the second quarter valued at approximately $33,000. Quarry LP grew its stake in shares of Pediatrix Medical Group by 54.1% during the third quarter. Quarry LP now owns 4,735 shares of the company’s stock worth $55,000 after buying an additional 1,662 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Pediatrix Medical Group by 47.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after acquiring an additional 1,524 shares during the last quarter. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MD has been the topic of a number of recent research reports. Mizuho increased their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. StockNews.com raised Pediatrix Medical Group from a “hold” rating to a “buy” rating in a report on Wednesday. UBS Group upped their price target on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Jefferies Financial Group raised their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, Truist Financial boosted their price objective on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Pediatrix Medical Group has an average rating of “Hold” and a consensus price target of $16.10.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.